March 20, 2014
KV Pharmaceutical Co. and the lead plaintiffs in a securities class action alleging the drugmaker hid U.S. Food and Drug Administration violations to inflate its share price have reached a $12.8 million settlement agreement that, if approved, would end more than five years of litigation, according to a filing in Missouri federal court Wednesday.
May 01, 2013
A Missouri federal judge refused Tuesday to dismiss a proposed class action against KV Pharmaceutical Co., ruling that top officials likely knew that company reports failed to disclose U.S. Food and Drug Administration regulatory violations and that investors were harmed by plummeting stock prices once the truth was revealed.